These data are corroborated, at least in part, by our previous reports showing enhanced subcutaneous-adipose tissue IRF5 expression in individuals with obesity and/or T2D in association with an inflammatory immune profile in the adipose tissue as well as by the data showing that macrophages and not adipocytes were the IRF5 expressors [13,14]. This evidence concerns the gene IRF5 and type 2 diabetes mellitus.